Insider · CIK 0001728970
Vivo Opportunity, LLC
Files at SLNO (SOLENO THERAPEUTICS INC), INM (InMed Pharmaceuticals Inc.), TERN (Terns Pharmaceuticals, Inc.). First filing Apr 3, 2024, latest Jul 16, 2026.
In brief
Vivo Opportunity, LLC files SEC Form 4 as 10% owner at INM (InMed Pharmaceuticals Inc.), and also at SLNO (SOLENO THERAPEUTICS INC), TERN (Terns Pharmaceuticals, Inc.). Since Apr 3, 2024, Vivo Opportunity, LLC has reported 3 open-market buys worth $434k and 2 open-market sells worth $54M, the latest filed on Jul 16, 2026.
A track record needs three past buys with six months of prices behind them; Vivo Opportunity, LLC has 0, so none is measured yet.
The newest scored trade: bought $32k of INM on Jul 14, 2026, filed Jul 16, 2026, scored 33 (weak). In the last 12 months: 3 buys worth $434k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
INM: InMed Pharmaceuticals Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | InMed Pharmaceuticals Inc. | $32k 20,546 shares | +3% | +154% from low-51% from high | |
| 15Weak | INMbuy InMed Pharmaceuticals Inc. | $10k 6,551 shares | +1% | +152% from low-52% from high | |
| 49Moderate | InMed Pharmaceuticals Inc. | $392k 249,227 shares | +51% | +162% from low-58% from high | |
| 42Moderate | SLNOsell SOLENO THERAPEUTICS INC | $52M 1,101,242 shares | -13% | - | |
| 17Weak | Terns Pharmaceuticals, Inc. | $2.8M 420,663 shares | -10% | - |
Transactions
Every row this insider has filed, 41 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 14, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Fund Holdings, L.P. | +4,882 | $1.55 | $7,567 | 729,277 | Jul 16, 2026 |
| Jul 14, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Cayman Fund, L.P. | +493 | $1.55 | $764 | 73,628 | Jul 16, 2026 |
| Jul 15, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Fund Holdings, L.P. | +13,761 | $1.55 | $21k | 743,038 | Jul 16, 2026 |
| Jul 15, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Cayman Fund, L.P. | +1,389 | $1.55 | $2,153 | 75,017 | Jul 16, 2026 |
| Jul 16, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Fund Holdings, L.P. | +19 | $1.55 | $29 | 743,057 | Jul 16, 2026 |
| Jul 16, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Cayman Fund, L.P. | +2 | $1.55 | $3 | 75,019 | Jul 16, 2026 |
| Jun 30, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Fund Holdings, L.P. | +545 | $1.54 | $839 | 718,989 | Jul 2, 2026 |
| Jun 30, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Cayman Fund, L.P. | +55 | $1.54 | $85 | 72,590 | Jul 2, 2026 |
| Jul 1, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Fund Holdings, L.P. | +3,946 | $1.55 | $6,116 | 722,935 | Jul 2, 2026 |
| Jul 1, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Cayman Fund, L.P. | +398 | $1.55 | $617 | 72,988 | Jul 2, 2026 |
| Jul 2, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Fund Holdings, L.P. | +1,460 | $1.55 | $2,263 | 724,395 | Jul 2, 2026 |
| Jul 2, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Cayman Fund, L.P. | +147 | $1.55 | $228 | 73,135 | Jul 2, 2026 |
| May 20, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Fund Holdings, L.P. | +51,056 | $1.56 | $80k | 543,129 | Jun 10, 2026 |
| May 20, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Cayman Fund, L.P. | +5,154 | $1.56 | $8,040 | 54,833 | Jun 10, 2026 |
| May 21, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Fund Holdings, L.P. | +30,882 | $1.69 | $52k | 574,011 | Jun 10, 2026 |
| May 21, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Cayman Fund, L.P. | +3,118 | $1.69 | $5,269 | 57,951 | Jun 10, 2026 |
| May 29, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Fund Holdings, L.P. | +16,164 | $1.57 | $25k | 590,175 | Jun 10, 2026 |
| May 29, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Cayman Fund, L.P. | +1,632 | $1.57 | $2,562 | 59,583 | Jun 10, 2026 |
| Jun 1, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Fund Holdings, L.P. | +14,838 | $1.55 | $23k | 605,013 | Jun 10, 2026 |
| Jun 1, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Cayman Fund, L.P. | +1,498 | $1.55 | $2,322 | 61,081 | Jun 10, 2026 |
| Jun 2, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Fund Holdings, L.P. | +20,753 | $1.52 | $32k | 625,766 | Jun 10, 2026 |
| Jun 2, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Cayman Fund, L.P. | +2,095 | $1.52 | $3,184 | 63,176 | Jun 10, 2026 |
| Jun 3, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Fund Holdings, L.P. | +7,069 | $1.55 | $11k | 632,835 | Jun 10, 2026 |
| Jun 3, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Cayman Fund, L.P. | +714 | $1.55 | $1,107 | 63,890 | Jun 10, 2026 |
| Jun 4, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Fund Holdings, L.P. | +6,125 | $1.57 | $9,616 | 638,960 | Jun 10, 2026 |
| Jun 4, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Cayman Fund, L.P. | +618 | $1.57 | $970 | 64,508 | Jun 10, 2026 |
| Jun 5, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Fund Holdings, L.P. | +49,966 | $1.57 | $78k | 688,926 | Jun 10, 2026 |
| Jun 5, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Cayman Fund, L.P. | +5,045 | $1.57 | $7,921 | 69,553 | Jun 10, 2026 |
| Jun 8, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Fund Holdings, L.P. | +29,518 | $1.52 | $45k | 718,444 | Jun 10, 2026 |
| Jun 8, 2026 | INM InMed Pharmaceuticals Inc. | POpen-market purchase Common Sharesindirect: By Vivo Opportunity Cayman Fund, L.P. | +2,982 | $1.52 | $4,533 | 72,535 | Jun 10, 2026 |
| Apr 29, 2024 | SLNO SOLENO THERAPEUTICS INC | SOpen-market sale Common Stockindirect: By Vivo Opportunity Fund Holdings, L.P. | -750,000 | $47.80 | $36M | 7,668,093 | May 1, 2024 |
| Apr 30, 2024 | SLNO SOLENO THERAPEUTICS INC | SOpen-market sale Common Stockindirect: By Vivo Opportunity Fund Holdings, L.P. | -351,242 | $45.13 | $16M | 7,316,851 | May 1, 2024 |
| Apr 1, 2024 | TERN Terns Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: By Vivo Opportunity Fund Holdings, L.P.10b5-1 | -136,255 | $6.99 | $952k | 4,203,957 | Apr 3, 2024 |
| Apr 1, 2024 | TERN Terns Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: By: Vivo Capital Fund VIII, L.P.10b5-1 | -39,411 | $6.99 | $275k | 1,997,146 | Apr 3, 2024 |
| Apr 1, 2024 | TERN Terns Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: By: Vivo Capital Surplus Fund VIII, L.P.10b5-1 | -5,451 | $6.99 | $38k | 275,772 | Apr 3, 2024 |
| Apr 2, 2024 | TERN Terns Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: By Vivo Opportunity Fund Holdings, L.P.10b5-1 | -76,346 | $6.65 | $508k | 4,127,611 | Apr 3, 2024 |
| Apr 2, 2024 | TERN Terns Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: By: Vivo Capital Fund VIII, L.P.10b5-1 | -22,084 | $6.65 | $147k | 1,975,062 | Apr 3, 2024 |
| Apr 2, 2024 | TERN Terns Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: By: Vivo Capital Surplus Fund VIII, L.P.10b5-1 | -3,050 | $6.65 | $20k | 272,722 | Apr 3, 2024 |
| Apr 3, 2024 | TERN Terns Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: By Vivo Opportunity Fund Holdings, L.P.10b5-1 | -103,870 | $6.20 | $644k | 4,023,741 | Apr 3, 2024 |
| Apr 3, 2024 | TERN Terns Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: By: Vivo Capital Fund VIII, L.P.10b5-1 | -30,047 | $6.20 | $186k | 1,945,015 | Apr 3, 2024 |
| Apr 3, 2024 | TERN Terns Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: By: Vivo Capital Surplus Fund VIII, L.P.10b5-1 | -4,149 | $6.20 | $26k | 268,573 | Apr 3, 2024 |
Questions about Vivo Opportunity, LLC
Answered from the filings on this page, as of the latest one.
Is Vivo Opportunity, LLC buying or selling?
In the last 12 months Vivo Opportunity, LLC reported 3 open-market buys worth $434k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $32k of INM on Jul 14, 2026. Grants, option exercises and tax withholding are not counted.
How did Vivo Opportunity, LLC's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Vivo Opportunity, LLC has 0.
Where does Vivo Opportunity, LLC file Form 4?
Vivo Opportunity, LLC has filed Form 4 at INM (InMed Pharmaceuticals Inc.); SLNO (SOLENO THERAPEUTICS INC); TERN (Terns Pharmaceuticals, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.